Latest Oncology News

Bria-IMT Plus Checkpoint Inhibition Leads to 52% 1-Year OS Rate in Heavily Pretreated Metastatic Breast Cancer

Bria-IMT Plus Checkpoint Inhibition Leads to 52% 1-Year OS Rate in Heavily Pretreated Metastatic Breast Cancer

July 8th 2025

Chris Ryan

Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.

Padeliporfin Vascular Targeted Photodynamic Therapy Safely Produces High Response Rates in Low-Grade Upper Tract Urothelial Cancer

Padeliporfin Vascular Targeted Photodynamic Therapy Safely Produces High Response Rates in Low-Grade Upper Tract Urothelial Cancer

July 8th 2025

Kyle Doherty

Padeliporfin vascular targeted photodynamic therapy was highly active with a tolerable safety profile in low-grade upper tract urothelial cancer.

MB-101 Receives FDA Orphan Drug Designation for Astrocytoma and Glioblastoma

MB-101 Receives FDA Orphan Drug Designation for Astrocytoma and Glioblastoma

July 8th 2025

Chris Ryan

The FDA granted orphan drug designation to MB-101 for recurrent diffuse and anaplastic astrocytoma and glioblastoma.

FDA Grants Orphan Drug Designation to FF-10832 for Biliary Tract Cancer

FDA Grants Orphan Drug Designation to FF-10832 for Biliary Tract Cancer

July 8th 2025

Ashling Wahner

FF-10832—an investigational liposomal formulation of gemcitabine—has received orphan drug designation from the FDA for biliary tract cancer.

Updated EHA-EMN Guidelines Include Melphalan Flufenamide for R/R Myeloma

Updated EHA-EMN Guidelines Include Melphalan Flufenamide for R/R Myeloma

July 8th 2025

Chris Ryan

The EHA-EMN guidelines now include melphalan flufenamide for certain patients with relapsed/refractory multiple myeloma.

Latest Oncology Videos

All Oncology News

Nogapendekin Alfa Inbakicept Plus BCG Approved in UK for BCG-Unresponsive NMIBC With CIS

July 8th 2025

Ashling Wahner

The combination of nogapendekin alfa inbakicept and BCG is now approved in the United Kingdom for the treatment of patients with NMIBC with CIS.

EXPLORER Shrinks the Time it Takes for Imaging to Spot Cancer

July 8th 2025

UC Davis Comprehensive Cancer Center

Cancer parametric PET imaging with radioactive tracers is reduced from an hour to 20 minutes

Menin Inhibitors Are Poised to Expand Targeted Therapeutics to Broader AML Populations

July 8th 2025

Courtney Flaherty

Naval G. Daver, MD, and Eytan M. Stein, MD, discuss how menin inhibitors may transform the treatment paradigm in NPM1-mutant and NUP98 fusion AML.

Bezuclastinib Improves TSS in Non-Advanced Systemic Mastocytosis

July 8th 2025

Chris Ryan

Bezuclastinib improved total symptom score vs placebo in non-advanced systemic mastocytosis, meeting the primary end point of the SUMMIT trial.

ASCO 2025 Plenary — MATTERHORN

July 7th 2025

Samantha A. Armstrong, MD

Drs Armstrong and Tawagi discussed key data from the phase 3 MATTERHORN trial, which were presented at the 2025 ASCO Annual Meeting.

Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC

July 7th 2025

Ashling Wahner

Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.

Ivosidenib Has Preliminary Real-World Activity in IDH1-Mutated Cholangiocarcinoma

July 7th 2025

Kyle Doherty

Ivosidenib was effective for the real-world treatment of patients with IDH1-mutated cholangiocarcinoma.

Partial Match Parity: Increasing the Donor Pool for Hematopoietic Stem Cell Transplantation

July 7th 2025

University of Miami Health System

Real-World Analysis Reveals Shorter Survival in KRAS G12C–Mutant Metastatic CRC After First-Line Treatment

July 7th 2025

Ashley Chan

A real-world analysis showed that patients with KRAS G12C–mutant mCRC had shorter OS and PFS after first-line treatment vs those with non-G12C mutations.

MAIC Analysis Suggests PFS, OS Advantage With Nivolumab/Ipilimumab Over Other First-Line IO Regimens in HCC

July 7th 2025

Courtney Flaherty

Efficacy results from a MAIC suggest potential benefit with nivolumab/ipilimumab over other first-line IO-based regimens in first-line unresectable HCC.

EU Approval Is Sought for Niraparib/Abiraterone Acetate Dual-Action Tablet in mHSPC With HRR Gene Alterations

July 7th 2025

Chris Ryan

European approval is being sought for the combination of niraparib, abiraterone acetate, and prednisone or prednisolone for HRR-mutated mHSPC.

FDA Approves Oncomine Dx Express Test for Tumor Profiling and as Companion Diagnostic for Sunvozertinib in NSCLC

July 7th 2025

Chris Ryan

The FDA approved the Oncomine Dx Express Test for tumor profiling and as a companion diagnostic for sunvozertinib in non–small cell lung cancer.

FDA Approves Y-90 Resin Microspheres for Unresectable HCC

July 7th 2025

Ashling Wahner

The FDA has approved SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Attention to Detail and Patience Are Key in the Job Search Process as Oncology Fellows

July 7th 2025

Kyle Doherty

An assistant professor at The Warren Alpert Medical School of Brown University discusses offers insights on the job search process following fellowship.

Evolving ADC Strategies in HER2– mBC: TROPION-Breast01 and Real-World Data From ASCO 2025

July 7th 2025

Rebecca A. Shatsky, MD

Panelists discuss how datopotamab deruxtecan from the TROPHY-PD-01 trial compares with sacituzumab govitecan, highlighting different toxicity profiles and the challenge of sequencing multiple antibody-drug conjugates (ADCs) with the same TROP2 payload.

See All News